Carbohydrate key to C. diff vaccine

German researchers have synthesized a carbohydrate on the surface of an extremely virulent strain of Clostridium difficile, a potentially deadly hospital-acquired infection, that could lead to a vaccine for the difficult-to-treat disease. Max Planck Institute scientists hope that they can develop a vaccine based on the carbohydrate that enables the body to recognize and respond to the threat of infection. Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.